AbbVie’s PARP inhibitor fails in PhIII trials
admin 20th April 2017 Uncategorised 0AbbVie’s experimental PARP inhibitor veliparib has failed to meet key targets in two late-stage studies testing its potential in lung and breast cancer.
More: AbbVie’s PARP inhibitor fails in PhIII trials
Source: News